BibTex format
@article{Samaranayake:2026:ehjopen/oeaf170,
author = {Samaranayake, CB and Chen, Y-C and Fang, M and Rhodes, CJ and Song, S and Sabrin, F and Ashek, A and Bonnici, K and Mukherjee, B and Howard, LS and Pinguel, J and Rawal, B and Semple, T and Price, LC and Wort, SJ and Rudd, T and Zhao, L and McCabe, C},
doi = {ehjopen/oeaf170},
journal = {Eur Heart J Open},
title = {GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.},
url = {http://dx.doi.org/10.1093/ehjopen/oeaf170},
volume = {6},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - AIMS: Vasorelaxant and anti-inflammatory properties of glucagon-like peptide-1 (GLP-1) agonists support their investigation in aiding the recovery of patients with acute pulmonary embolism (PE) at risk of worse outcomes. METHODS: We undertook a four week non-randomized, controlled open-label study examining proteomic changes, markers of vascular inflammation and exploratory imaging endpoints in response to GLP-1 agonist, semaglutide (0.25mg weekly) added to standard of care anticoagulation in patients with intermediate high-risk PE. RESULTS: 44 plasma proteins were downregulated in response to semaglutide that were significantly enriched for glycoproteins (false discovery rate q < 0.01). Glycopeptide analysis of highly abundant glycoproteins between diagnosis and follow-up demonstrated a reduction in glycopeptide abundance suggesting protein deglycosylation as a possible mechanism of glycoprotein down-regulation. Down-regulated proteins included regulators of metabolic stress and complement pathway intermediates, which were at higher abundance in PE patients at diagnosis compared to age and sex-matched controls without PE (all P < 0.001). Exploratory evaluation of radiological markers of right ventricular dysfunction improved from baseline to follow-up only in patients who received semaglutide (P < 0.01). CONCLUSIONS: These findings suggest merit in wider investigation of immunometabolic changes in the plasma proteome during acute PE recovery and their potential relevance to modulation using GLP-1 agonists. REGISTRATION: The study was registered under clinicaltrials.org (NCT06118203).
AU - Samaranayake,CB
AU - Chen,Y-C
AU - Fang,M
AU - Rhodes,CJ
AU - Song,S
AU - Sabrin,F
AU - Ashek,A
AU - Bonnici,K
AU - Mukherjee,B
AU - Howard,LS
AU - Pinguel,J
AU - Rawal,B
AU - Semple,T
AU - Price,LC
AU - Wort,SJ
AU - Rudd,T
AU - Zhao,L
AU - McCabe,C
DO - ehjopen/oeaf170
PY - 2026///
TI - GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.
T2 - Eur Heart J Open
UR - http://dx.doi.org/10.1093/ehjopen/oeaf170
UR - https://www.ncbi.nlm.nih.gov/pubmed/41536961
VL - 6
ER -